Oakwood Laboratories L.L.C. - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 27

Oakwood Laboratories L.L.C. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Oakwood Laboratories L.L.C. - Product Pipeline Review - 2012” provides data on the Oakwood Laboratories L.L.C.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Oakwood Laboratories L.L.C.’s corporate website, SEC filings, investor presentations and featured press releases, both from Oakwood Laboratories L.L.C. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oakwood Laboratories L.L.C. - Brief Oakwood Laboratories L.L.C. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oakwood Laboratories L.L.C. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oakwood Laboratories L.L.C. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oakwood Laboratories L.L.C.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oakwood Laboratories L.L.C.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oakwood Laboratories L.L.C. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oakwood Laboratories L.L.C.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oakwood Laboratories L.L.C..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oakwood Laboratories L.L.C. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Oakwood Laboratories L.L.C.; Oakwood Laboratories L.L.C. - Key Therapeutics; Oakwood Laboratories L.L.C. - Pipeline Overview and Promising Molecules; Oakwood Laboratories L.L.C. - News; Oakwood Laboratories L.L.C. - Latest Updates; Oakwood Laboratories L.L.C. - Pipeline; Oakwood Laboratories L.L.C. - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
Oakwood Laboratories L.L.C. Snapshot 5
Oakwood Laboratories L.L.C. Overview 5
Key Information 5
Key Facts 5
Oakwood Laboratories L.L.C. – Research and Development Overview 6
Key Therapeutic Areas 6
Oakwood Laboratories L.L.C. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Oakwood Laboratories L.L.C. – Pipeline Products Glance 10
Oakwood Laboratories L.L.C. – Late Stage Pipeline 10
Registration Filed Products/Combination Treatment Modalities 10
Oakwood Laboratories L.L.C. – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Oakwood Laboratories L.L.C. – Drug Profiles 12
Leuprolide 22.5 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Leuprolide 3.75 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Leuprolide 30 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Leuprolide 45 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Leuprolide 7.5 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Octreotide 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Risperidone 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Oakwood Laboratories L.L.C. – Pipeline Analysis 20
Oakwood Laboratories L.L.C. – Pipeline Products by Therapeutic Class 20
Oakwood Laboratories L.L.C. – Pipeline Products by Route of Administration 21
Oakwood Laboratories L.L.C. – Pipeline Products By Mechanism of Action 22
Oakwood Laboratories L.L.C. – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Financial Deals Landscape 24
Oakwood Laboratories L.L.C., Deals Summary 24
Oakwood Laboratories L.L.C., Pharmaceuticals & Healthcare, Deal Details 25
Licensing Agreements 25
Oakwood Labs Enters Into Licensing Agreement With Santen Pharma 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables
Oakwood Laboratories L.L.C., Key Information 5
Oakwood Laboratories L.L.C., Key Facts 5
Oakwood Laboratories L.L.C. – Pipeline by Indication, 2012 7
Oakwood Laboratories L.L.C. – Pipeline by Stage of Development, 2012 8
Oakwood Laboratories L.L.C. – Monotherapy Products in Pipeline, 2012 9
Oakwood Laboratories L.L.C. – Filed, 2012 10
Oakwood Laboratories L.L.C. – Pre-Clinical, 2012 11
Oakwood Laboratories L.L.C. – Pipeline By Therapeutic Class, 2012 20
Oakwood Laboratories L.L.C. – Pipeline By Route of Administration, 2012 21
Oakwood Laboratories L.L.C. – Pipeline Products By Mechanism of Action, 2012 22
Oakwood Laboratories L.L.C., Other Locations 23
Oakwood Laboratories L.L.C., Deals Summary 24
Oakwood Labs Enters Into Licensing Agreement With Santen Pharma 25

List of Figures
Oakwood Laboratories L.L.C. – Pipeline by Indication, 2012 7
Oakwood Laboratories L.L.C. – Pipeline by Stage of Development, 2012 8
Oakwood Laboratories L.L.C. – Monotherapy Products in Pipeline, 2012 9
Oakwood Laboratories L.L.C. – Pipeline By Therapeutic Class, 2012 20
Oakwood Laboratories L.L.C. – Pipeline By Route of Administration, 2012 21
Oakwood Laboratories L.L.C. - Pipeline Products By Mechanism of Action, 2012 22

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• Amazon - Point of Realization in 2013?
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• United Parcel Service - IT Sales Opportunities - 2009
• Union Pacific Corporation - IT Sales Opportunities - 2009
• SunGard - Profile - US
• eBay - Strong Execution
• TeliaSonera: Transforming its Business